The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice

Toxicol Ind Health. 2013 Jun;29(5):404-17. doi: 10.1177/0748233711434955. Epub 2012 Feb 8.

Abstract

The study aimed to investigate the antitumor effect of tetrodotoxin (TTX) and/or doxorubicin (DOX) on Ehrlich ascites carcinoma (EAC)-bearing mice through the investigated biochemical parameters. TTX and/or DOX with or without N-acetylcystiene were administrated after 10 days into EAC-female mice for a period of 2 weeks in six equal doses. Treatment with TTX or DOX caused a significant decrease in the mean tumor weight and an increase in the cumulative mean survival time when compared with EAC group. All the treatments reduced the elevated liver tumor markers and increased liver antioxidant enzymes under investigation in comparison with EAC. Hepatic cells, suffered severely from degeneration and karriolysis in EAC group, revealed some improvement as appearance of healthy hepatocytes by TTX treatment. The present results suggested that TTX had a more powerful inhibitor effect on EAC growth than DOX and TTX plus DOX treatments reflected by antitumor biochemical and histological studies.

Keywords: Ehrlich ascites carcinoma; Mice; antitumor study; apoptosis; doxorubicin; liver histology; tetrodotoxin.

MeSH terms

  • Analysis of Variance
  • Animals
  • Antibiotics, Antineoplastic / pharmacology*
  • Apoptosis / drug effects
  • Carcinoma, Ehrlich Tumor / drug therapy*
  • Carcinoma, Ehrlich Tumor / pathology
  • Doxorubicin / pharmacology*
  • Drug Screening Assays, Antitumor
  • Female
  • Histocytochemistry
  • Liver / drug effects
  • Liver / pathology
  • Mice
  • Tetrodotoxin / pharmacology*

Substances

  • Antibiotics, Antineoplastic
  • Tetrodotoxin
  • Doxorubicin